默沙东：利普卓联合疗法在华获批用于治疗前列腺癌患者

Core Viewpoint - Merck has received approval from the National Medical Products Administration of China for its PARP inhibitor, Olaparib, in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) carrying germline or somatic BRCA mutations (gBRCAm or sBRCAm) [1] Group 1 - The approval of this combination therapy will provide advanced treatment options for more prostate cancer patients [1]